O free radicals play a significant role in acute and chronic inflammatory disease [1] . In patients with inflammatory joint disease, there are abnormalities consistent with oxidative damage [2] . There is now much evidence, both direct and indirect, implicating reactive oxygen species in the pathogenesis of inflammatory synovitis, especially in rheumatoid arthritis (RA) [3] [4] [5] . There is also evidence linking reactive oxygen species with cartilage damage [6, 7] . Patients with RA have depressed serum levels of the antioxidant, and a low antioxidant level is a risk factor for RA [8] . Therefore, oxygen free radicals are one of the major contributors to inflammation in RA.
Pentosidine is one of the advanced glycation end-products (AGEs) [9] . Its significant elevation was first observed in tissues in diabetes mellitus [10] . Pentosidine is also elevated in serum and urine in diabetic patients [11] [12] [13] . It was secondly found that pentosidine was elevated in patients with end-stage renal failure [10, 12, 14] . In uraemia, the extent of the elevation of serum pentosidine is much higher than that found in diabetes mellitus. In addition, during the ageing process, AGEs accumulate in extracellular matrix and cause insolubility and protease resistance of extracellular matrix proteins. It has been demonstrated that pentosidine accumulates in human tissues with age [15] [16] [17] . There was also evidence that pentosidine was associated with Alzheimer disease pathology [18] . Therefore, pentosidine significantly relates to ageing and is regarded as one of the senescence cross-links.
Pentosidine is formed by sequential glycosylation and oxidation reactions. The formation of pentosidine requires aerobic conditions and anti-oxidative conditions inhibit the formation of pentosidine [19] [20] [21] . Therefore, it is hypothesized that pentosidine formation is accelerated in the disease under oxidative stress.
Because oxidative stress and free radicals play a significant role in tissue damage and inflammation in RA, and pentosidine formation is accelerated by oxidation conditions, pentosidine is supposed to be implicated in the disease of RA. It was demonstrated that pentosidine levels were elevated in cartilage in RA and suggested that oxidative stress was related to the elevation of pentosidine in the cartilage of RA [22] .
We have investigated pentosidine levels in serum and urine from the diseased conditions, and recently developed the direct method by HPLC with column switching to measure pentosidine in body fluids [23] . The aim of this study is to elucidate the significance of pentosidine levels in serum and urine in RA, and its relationship to inflammation status or activity of RA.
SUBJECTS AND METHODS

Subjects
The RA group consisted of 77 female patients aged 35-69 yr (mean 2 .. = 50.9 2 8.2). RA patients were diagnosed according to the American Rheumatism Association 1987 revised criteria for the classification of RA. They were recruited at the out-patient clinic in the Department of Orthopaedic Surgery at Hamamatsu University School of Medicine. They were all ambulatory. The patients who had diabetes mellitus and had abnormal levels of serum blood urea nitrogen (BUN) or creatinine were excluded from the study.
The control group consisted of 62 healthy females aged 39-60 yr (49.6 2 6.2). There was no significant difference in age between RA patients and control subjects. All subjects had no previous history of diabetes mellitus and renal disease, and were currently receiving no medication. The procedures followed were in accordance with the principles of the Declaration of Helsinki in 1975, as revised in 1983.
Collection of serum and urine samples
Blood and urine were collected on the same day between 9:00 and 11:00 a.m. from all subjects and patients, who had no dietary restriction. Blood was immediately centrifuged, and serum and urine were stored at −30°C until the assay.
Clinical features, blood biochemistry and disease activity in RA
RA patients were classified into stage 1-4 and class 1-4 according to Steinbrocker [24] . Stage was determined based on roentgenological findings of hands and class was determined based on functional capacity; 1 is the slightest and 4 is the severest degree of disease. Serum creatinine, BUN, uric acid (UA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and rheumatoid factor (RF) were measured by routine laboratory methods. The Lansbury Index (LI) was determined based on the duration of morning stiffness, ESR (value at 1 h), grip strength (mmHg) and joint score [25, 26] . Joint score was determined as the sum of scores for painful, tender or swollen joints [25, 26] . According to the treatment with steroid, the patient was classified as a user or non-user of steroid. The patients who were treated with oral steroid for the last 6 months were defined as users.
Measurements of serum and urinary pentosidine
Pentosidine was measured by the direct HPLC method with column switching described elsewhere [23] . The samples were placed directly onto a gel filtration pre-column (TSK pre-column PW, 4.6 mm × 3.5 cm, TOSOH, Tokyo, Japan), selecting the eluate fraction containing pentosidine, and introducing this fraction into a reversed-phased column (TSK-GEL ODS-80T, 4.6 mm × 15 cm, TO-SOH) by use of a switching valve. The urine sample was directly injected into the HPLC column, whereas the serum sample was injected after its acid hydrolysis. The concentrations of pentosidine in serum were expressed as nmol/l. The concentrations of pentosidine in urine were corrected by the concentrations of urine creatinine, and expressed as mmol/mol creatinine. Urinary creatinine content was measured by a routine laboratory method.
Statistical analysis
The statistical significance of differences was determined by non-parametric statistics using MannWhitney U-tests between two groups and KruskalWallis among more than two groups. Simple regression was performed for univariate correlation and the statistical significance of correlation was determined by the Spearman rank correlation test. As multivariate analyses, a multiple regression and a stepwise regression analyses were used to determine the relationship between serum and urinary pentosidine and the factor of clinical features, blood biochemistry and activity of RA. The factors used for both analyses were age, duration of the disease, stage, class, CRP, RF, ESR, duration of morning stiffness, joint score and LI. The analysis was performed with StatView II (Abacus Concepts, Inc., Berkeley, CA, USA) on a Macintosh computer (Apple Computer, Inc., Cupertino, CA, USA). Values of P Q 0.05 were considered significant.
RESULTS
Typical chromatograms of pentosidine in serum and urine from a RA patient are shown in Fig. 1 .
Serum levels of pentosidine in RA (mean 2 .. = 150.1 2 112.1 nmol/l) were significantly higher than in controls (81.7 2 14.9) (P Q 0.01). Urinary levels of pentosidine in RA (10.7 2 8.0 mmol/mol creatinine) were significantly higher than in controls (3.8 2 1.5) (P Q 0.001).
There was a significant correlation between serum pentosidine and urinary pentosidine in RA (serum pentosidine = 7.518 × urinary pentosidine + 69.908, r = 0.633, P Q 0.001), but not in controls (serum pentosidine = 1.19 × urinary pentosidine + 77.126, r = 0.110). Serum and urinary pentosidine were significantly related with age in RA, although they were not related with age in controls (Fig. 2) . Table I shows the levels of serum and urinary pentosidine in the patients classified by stage or class. There was no significant difference in serum and urinary pentosidine among stages. However, serum and urinary pentosidine in stages 2 and 3 tended to be higher than those in stages 1 and 4. The patients classified as class 4 were not included in this study, because it is difficult for the patients with class 4 to visit an out-patient clinic routinely. There was a significant difference in serum and urinary pentosidine among classes 1-3. There was no significant difference in age among stage and class.
In RA, we examined the correlations between clinical features, blood biochemistry or disease activities of RA, and serum or urinary pentosidine (Table II) . In RA patients, the duration of RA disease ranged from 6 months to 32 yr (mean 2 .. = 11.3 2 6.7 yr). There Simple regression analysis was performed and statistical probability was determined with the Spearman rank correlation method. n means the number of the patients used for each analysis. s-pen and u-pen are serum pentosidine and urinary pentosidine, respectively. There was no difference in s-pen and u-pen among stages, but there was a significant difference in s-pen and u-pen among classes (P Q 0.01) by Kruskal-Wallis. There was no patient in class 4. was not a significant correlation between serum pentosidine and duration, or between urinary pentosidine and duration. There were significant correlations between CRP, RF, joint score and LI, and serum and urinary pentosidine. There was a significant correlation between serum pentosidine and ESR, but not between urinary pentosidine and ESR. There were no significant correlations between the duration of morning stiffness, serum creatinine, BUN and UA, and serum or urinary pentosidine. After RA patients were divided into four quartile groups according to the values of the measurements for RA activity, which were CRP, RF, ESR and LI, the levels of serum and urinary pentosidine were compared between the highest quartile group and the lowest quartile group (Table III) . Serum and urinary pentosidine in the highest quartile of CRP, ESR, RF and LI were higher than those in the lowest group; however, only those in RF and LI were statistically significant. There was no difference with age in the highest and lowest quartile groups of ESR, RF and LI, except CRP. Because there was a significant difference with age in the highest and lowest quartile groups of CRP, age was matched in groups of CRP in Table III. In RA patients, 15 patients were steroid users (age, mean 2 .. = 52.8 2 5.8) and 62 patients were nonusers (50.5 2 8.6). Serum pentosidine in steroid users (mean 2 .. = 202.3 2 129.0 nmol/l) was significantly higher than in non-steroid users (137.4 2 105.1) (P Q 0.05). Urinary pentosidine in steroid users (15.5 2 10.0 mmol/mol creatinine) was also significantly higher than in non-steroid users (9.5 2 7.0) (P Q 0.01).
To examine the factors which affect the levels of serum or urinary pentosidine, multivariate analyses were performed. In a multiple regression analysis, the equation obtained was significant for serum or urinary pentosidine (Table IV) . However, there was only one significant independent factor, which was age for urinary pentosidine. A stepwise regression analysis showed that LI was accounted for by serum pentosidine, and age and LI were accounted for by urinary pentosidine (Table V) .
DISCUSSION
There have been a few reports studying pentosidine in RA [22] . This is the first report measuring serum and urinary pentosidine in RA. This study demonstrated a significant elevation of pentosidine in serum and urine in RA.
In diabetes mellitus, the pathophysiological features of complications relate to the abnormal glycosylation products with protein. Chronic hyperglycaemia leads to the accumulation of non-enzymatically derived glycosylation products of proteins. Glucose forms chemically reversible early glycosylation products with protein, known as Schiff base. These Schiff bases then rearrange to form more stable, but chemically reversible, Amadori-type early glycosylation products. These early glycosylation products undergo a slow, time-consuming rearrangement to form irreversible AGEs. AGEs are believed to contribute to diabetic complications [27] . Pentosidine is one of those AGEs and is elevated in tissues, serum and urine in diabetic patients [10] [11] [12] [13] 27] . Pentosidine is present in small quantities in tissues [9, 28] ; however, pentosidine may be a generalized marker of proteins modified with AGEs because of a strong relationship between pentosidine and diabetes mellitus. Pentosidine was also elevated in tissues and body fluids from patients with end-stage renal failure [10, 12, 14] . In uraemia, the extent of the elevation of plasma pentosidine is much higher than that found in diabetes mellitus. However, the mechanism that elevates pentosidine in uraemia is still unknown. There may be two reasons for the elevation of pentosidine in the patients with chronic renal failure. The fact that pentosidine was very high in collagen [10] and red blood cells [12] from uraemic patients suggests that pentosidine's precursors are retained by the diseased kidney and the accumulation of pentosidine precursors may cause an increase in the synthesis of pentosidine. However, an increase in the synthesis of pentosidine alone is not likely to cause the extreme elevation of pentosidine in uraemic serum. Because serum pentosidine levels did not change after haemodialysis in end-stage renal failure, haemodialysis could not eliminate pentosidine from serum [29] . It was reported that pentosidine circulates as a protein-bound form in blood and is excreted in its free form into urine [13, 14, 23] . It is likely that pentosidine is mostly catabolized in the kidney and the diseased kidney may retain pentosidine in the blood circulation.
The sugar precursor of pentosidine in vivo has not been identified. The studies in vitro have demonstrated that pentosidine can be generated in long-term incubation of amino acids with ribose, glucose, fructose and several pentoses, and metabolites of ascorbic acid [19, 20] . The evidence of a requirement for oxygen in the formation of pentosidine in vitro from glucose, ribose, ascorbate and Amadori products indicates that oxidation is required at some stage in the formation of pentosidine [19, 20] . Because the enhanced oxidation in RA exhibits abnormalities consistent with oxidative injury, such as end-products of lipid peroxidation and oxidized ascorbic acid [1] , ascorbic acid or its metabolites, especially oxidized ascorbic acid, are possible source of pentosidine in RA.
With age, the physical and chemical properties of extracellular matrix result in loss of elasticity and decreased susceptibility to proteinase, and in accumulation of yellow or brown pigmentation in the tissues. The senescence cross-links are believed to play a significant role in those changes in the extracellular matrix. It has been reported that the content of pentosidine in dura mater [9] , skin [10] , lens protein [11] , cartilage [15] , glomerular basement membrane [30] and aorta [31] increased with age throughout life. Therefore, pentosidine is regarded as one of the senescence cross-links [32] . We previously revealed that urinary excretion of pentosidine remained at a plateau until age 70 and increased exponentially with age in older people [33] . In this study, there was no significant correlation between urinary pentosidine and age in normal subjects whose ages ranged from 39 to 60 yr. In contrast, serum and urinary pentosidine increased with age in RA patients whose ages ranged from 35 to 69 yr.
Ageing in the patients with RA is clinically observed to be accelerated, and mortality and other findings suggest that RA is a disease of accelerated ageing [34] . Therefore, the age-related increase in pentosidine is pronounced in RA with accelerated ageing.
Serum and urinary pentosidine in stages 2 and 3 were higher than those in stages 1 and 4, although there was no statistical significance. Those in stage 4 were not high, the same levels as those in stage 1. Because stage 4 means ankylosis of joints, the activity of RA in the patients with stage 4 generally seems to be burned out. Therefore, lower levels of pentosidine in the patients with stage 4 might reflect no high activity of RA. On the other hand, serum and urinary pentosidine increased with class grading. Because class was defined according to the functional capacity, the degree of immobility of the patients increases with class grading. Because decreased physical activity is one of the major aspects of ageing, accelerated ageing may result in the elevation of pentosidine in patients with a higher grade of class.
The concentrations of serum and urinary pentosidine did not relate to the duration of disease in RA. In this study, the duration of disease did not correlate with either of the parameters for activity of RA, which were CRP, ESR and joint score (data not shown). Because RA patients generally have periods of restoration and deterioration of the disease alternately, the duration of disease does not simply relate to the activity of RA.
Simple regression analysis revealed that serum and urinary pentosidine correlated significantly with the parameters of activity of RA which were CRP, ESR, RF, joint score and LI. An exception was no relationship between urinary pentosidine and ESR. Among them, moderate correlations were observed between urinary pentosidine and CRP (r = 0.438), serum pentosidine and LI (0.386), serum pentosidine and CRP (0.356), and urinary pentosidine and LI (0.321). Because serum and urinary pentosidine in the highest quartile of parameters for activity of RA (CRP, ESR, RF and LI) were 1.5-to 2.4-fold higher than those in the lowest quartile of its distribution, serum and urinary pentosidine were more elevated in patients with more active RA than in those with less active RA. Therefore, the levels of serum and urinary pentosidine relate to the activity of RA.
Thirty-four per cent of the changes in serum pentosidine were accounted for by age, duration of disease, stage, class, CRP, ESR, RF, morning stiffness, joint score and LI, with LI being the strongest independent variable when analysed by a multiple regression. The changes in urinary pentosidine were 31.7% accounted for by the same variables, with age being the strongest independent variable. A stepwise regression analysis found that only LI is accounted for by the changes in serum pentosidine, and age and LI were accounted for by the changes in urinary pentosidine. Those multivariate analyses indicate that pentosidine levels are less affected by a single parameter for RA activity, but affected by an integrated activity score of LI, and urinary pentosidine is also affected by age. Therefore, variables of pentosidine levels could not only be explained by known parameters for activity, but also the other unknown factors. Accordingly, pentosidine may be a unique indicator for evaluating the disease status or activity of RA.
In conclusion, pentosidine was elevated in serum and urine from the patients with RA. Serum and urine levels of pentosidine correlated significantly with the activity of RA, and serum and urinary pentosidine may be a significant and novel marker for evaluating the disease status and the activity of RA.
